title: Evaluation of matrix type mucoadhesive tablets containing indomethacin for buccal application.
abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are administered for pain relief from oral mucositis. However, the systemic administration of NSAIDs is limited due to systemic side effects. To avoid these side effects and treat local lesions effectively, a matrix type mucoadhesive tablet was developed. A mixture of hard fat, ethylcellulose (EC) and polyethylene glycol (PEG) was used as a matrix base, and indomethacin (IMC) was used as the principal agent. In tablets consisting of hard fat, EC and IMC, the drug release was sustained. In tablets consisting of hard fat, EC, considerable amounts of PEG and IMC, the drug release was relatively increased and IMC existed as the molecular phase or in an amorphous state. The in vitro adhesive force of the tablets consisting of hard fat, EC, considerable amounts of PEG and IMC was significantly increased as compared with the tablets consisting of hard fat and IMC. A significantly high tissue concentration and significantly low plasma concentration were observed after buccal administration of this matrix type mucoadhesive tablet as compared with that after oral administration of IMC. Thus, the matrix type mucoadhesive tablet has good potential as a preparation for the treatment of pain due to oral aphtha.
authors.affiliation: Department of Drug Delivery Research, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan. ikeuchiyuri@yahoo.co.jp
authors.forename: Yuri
authors.initials: Y
authors.lastname: Ikeuchi-Takahashi
authors.forename: Masanaho
authors.initials: M
authors.lastname: Sasatsu
authors.forename: Hiraku
authors.initials: H
authors.lastname: Onishi
mesh_terms: D000042:Absorption; D000268:Adhesiveness; D000278:Administration, Buccal; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D002482:Cellulose / Q000031:analogs & derivatives / Q000737:chemistry; D004355:Drug Stability; D005223:Fats / Q000737:chemistry; D007213:Indomethacin / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D008297:Male; D009061:Mouth Mucosa / Q000378:metabolism; D011092:Polyethylene Glycols / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley; D013607:Tablets
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005223:Fats; D013607:Tablets; D011092:Polyethylene Glycols; C013517:ethyl cellulose; D002482:Cellulose; D007213:Indomethacin
keywords: Buccal; Controlled release; Formulation; Mucosal delivery; Solid dosage form; X-ray powder diffractometry